CompletedNCT00116259
Aripiprazole for young people with bipolarity and ADHD
About this title
Aripiprazole in Children and Adolescents With Bipolar Disorder and Attention Deficit Hyperactivity Disorder (ADHD)
Read the official source — NCT00116259Medication studyAges 8–17Brazil
Understand this study
Who was this study for?
Listed age limits: 8 years to 17 years.
- Listed locations
- Porto Alegre - BrazilSee all locations and recruitment
Study information
Study start dateMarch 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 50
- Sponsor
- Federal University of Rio Grande do Sul
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- Brazil
- Age range
- From 8 Years to 17 Years
- Official registry ID
- NCT00116259
- Official title
Show the full official title
Aripiprazole in Children and Adolescents With Bipolar Disorder and ADHD: A Randomized Double Blind Placebo Controlled Trial
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Porto Alegre - Brazil
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Federal University of Rio Grande do Sul, a university.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole.
Who was this study for?
Listed age limits: 8 years to 17 years.
